Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Tumor Microenvironment Market to Reach Over $2.7 Billion by 2030 - Rising Demand for Personalized Oncology Therapies and Next-Gen Immunotherapies Driving the Industry

globenewswire.com
PFE Pfizer Inc. is mentioned as a key player in the growing Tumor Microenvironment (TME) market, indicating its involvement in this sector without specific positive or negative performance indicators in the article. JNJ Johnson & Johnson is listed as a major company within the Tumor Microenvironment (TME) market. The article does not provide specific details on their performance or outlook within this market. MRK Merck & Co. Inc. is identified as a key industry player in the Tumor Microenvironment (TME) market. The article mentions its presence but offers no specific sentiment regarding its performance or future prospects. ABBV AbbVie Inc. is named as one of the major companies in the Tumor Microenvironment (TME) market. The article does not provide any specific sentiment or performance data related to AbbVie. CHRS Coherus BioSciences Inc. is mentioned for acquiring Surface Oncology Inc., indicating strategic expansion in the immuno-oncology space targeting the TME. The article does not provide specific sentiment on Coherus's performance.

Tumor Microenvironment Market to Reach Over $2.7 Billion by 2030 - Rising Demand for Personalized Oncology Therapies and Next-Gen Immunotherapies Driving the Industry Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Microenvironment Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The tumor microenvironment (TME) market has witnessed substantial growth, with its size projected to expand from $1.54 billion in 2025 to $1.73 billion in 2026 at a CAGR of 12.4%. This growth during the historical period is primarily fueled by advancements in cancer biology research, enhanced understanding of tumor-immune interactions, and a surge in immuno-oncology pipelines. Furthermore, the availability of cutting-edge laboratory technologies has bolstered academic and clinical cancer research.

Looking ahead, the TME market is poised for rapid growth, expected to reach $2.73 billion by 2030, maintaining a robust CAGR of 12.1%. This forecasted expansion is driven by increasing investments in personalized oncology therapies and a heightened demand for next-generation immunotherapies. The expansion of translational cancer research and collaborative efforts between pharmaceutical companies and research institutes further contribute to market growth. Notably, key trends include a focus on immune cell modulation strategies, the development of TME-targeted therapies, and the enhancement of molecular profiling technologies.

The rising incidence of cancer, largely driven by aging populations, is a significant factor propelling the TME market. As the prevalence of cancer escalates, the need for advanced treatment options becomes more critical. The TME facilitates cancer progression by supporting immune evasion and enhancing tumor proliferation. For instance, the Australian Institute of Health and Welfare reported a substantial rise in cancer diagnoses in Australia, underscoring the increasing demand for innovative cancer therapies.

Key industry players are leveraging targeted therapies to enhance treatment efficacy and address resistance mechanisms. Aubex Therapeutics Inc. introduced an innovative class of compounds aimed at revolutionizing cancer treatment by modulating the TME. This approach enhances the immune response and disrupts tumor growth and metastasis processes. Similarly, Coherus BioSciences Inc. acquired Surface Oncology Inc., emphasizing the significance of expanding immuno-oncology portfolios targeting the TME.

The competitive landscape of the TME market includes major companies such as Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., and Bayer AG, among others. Geographically, North America was the largest market in 2025, while Asia-Pacific is anticipated to experience the fastest growth. The market spans regions including Asia-Pacific, Western Europe, Eastern Europe, and North America, covering countries like the USA, China, Germany, and the UK.

Reasons to Purchase:

Report Scope

Markets Covered:

Subsegments:

Companies Mentioned: Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., among others.

Countries: Including Australia, China, Germany, USA, and more.

Regions: Asia-Pacific, Western Europe, North America, and others.

Time Series: Five years historic and ten years forecast data.

Data: Market size ratios, GDP proportions, and per capita expenditure.

Data Segmentation: Country and regional data, market share and segments.

Key Attributes

The companies featured in this Tumor Microenvironment market report include:

For more information about this report visit https://www.researchandmarkets.com/r/fw2a9a

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment